SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS
- 18 June 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (25), 2271-2285
- https://doi.org/10.1182/blood.2019001963
Abstract
SETD2, the histone H3 lysine 36 methyltransferase previously identified by us, plays an important role in the pathogenesis of hematologic malignancies, but its role in MDS has been unclear. In this study, we show that low expression of SETD2 correlates with shortened survival in MDS patients and that the SETD2 levels in CD34+ bone marrow (BM) cells of MDS patients can be increased by decitabine. We knock out Setd2 in the NUP98-HOXD13 (NHD13) transgenic mice, which phenocopies human MDS, and demonstrate that loss of Setd2 accelerates the transformation of MDS into acute myeloid leukemia (AML). Loss of Setd2 enhances the ability of NHD13+ HSPCs to self-renew, with increased symmetric self-renewal division and decreased differentiation/cell death. The growth of MDS-associated leukemia cells can be inhibited though increasing H3K36me3 level by using epigenetic modifying drugs. Furthermore, Setd2 deficiency upregulates hematopoietic stem cell (HSC) signaling and downregulates myeloid differentiation pathways in the NHD13+ HSPCs. Our RNA-seq and ChIP-seq analysis indicate that S100a9, the S100 calcium-binding protein, is a target gene of Setd2 and that the addition of recombinant S100a9 weakens the effect of Setd2 deficiency in the NHD13+ HSPCs. In contrast, downregulation of S100a9 leads to decreases of its downstream targets, including IƙBα and Jnk, which influence the self-renewal and differentiation of HSPCs. Therefore, our results demonstrate that SETD2 deficiency predicts poor prognosis in MDS and promotes the transformation of MDS into AML, which provides a potential therapeutic target for MDS-associated acute leukemia.This publication has 41 references indexed in Scilit:
- The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaNature Reviews Cancer, 2016
- BCOR regulates myeloid cell proliferation and differentiationLeukemia, 2016
- Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformationNature Communications, 2014
- Genomic landscape of CD34 + hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markersProceedings of the National Academy of Sciences of the United States of America, 2014
- Age-related epigenetic drift in the pathogenesis of MDS and AMLGenome Research, 2014
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013
- Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13–driven mouse modelBlood, 2012
- ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene RepressionCancer Cell, 2012
- Myelodysplastic syndromes: the complexity of stem-cell diseasesNature Reviews Cancer, 2007
- NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemiaBlood, 2005